• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study
CONCLUSIONSOur findings contribute to the understanding that second-line SU for glucose lowering are unlikely to increase CV risk or all-cause mortality. Given their potent efficacy, microvascular benefits, cost effectiveness, and widespread use, this study supports that SU should remain a part of the global diabetes treatment portfolio.
Source: Diabetes Care - March 21, 2023 Category: Endocrinology Source Type: research

CRP, C-Peptide, and Risk of First-Time Cardiovascular Events and Mortality in Early Type 2 Diabetes: A Danish Cohort Study
CONCLUSIONSThe finding of high hs-CRP as a stronger prognostic biomarker of all-cause mortality than of CVEs may facilitate improved early detection and prevention of deadly diseases besides CVEs. Conversely, elevated C-peptide as a strong CVE biomarker supports the need to target hyperinsulinemia/insulin resistance in T2D CVE prevention.
Source: Diabetes Care - March 17, 2023 Category: Endocrinology Source Type: research

30-Year Cardiovascular Disease in Type 1 Diabetes: Risk and Risk Factors Differ by Long-term Patterns of Glycemic Control
CONCLUSIONSThese risk factor differences suggest that pathways to CVD may differ by glycemic control, potentially resulting in important implications for prognosis in type 1 diabetes.
Source: Diabetes Care - November 15, 2021 Category: Endocrinology Source Type: research

Gestational Diabetes Mellitus and the Risks of Overall and Type-Specific Cardiovascular Diseases: A Population- and Sibling-Matched Cohort Study
CONCLUSIONSA history of GDM was associated with increased risks of overall and specific CVDs. Increased risks were partly explained by subsequent type 2 diabetes, and the need to identify other pathways remains important. Continuous monitoring of women with a history of GDM, especially those with prepregnancy obesity or maternal history of CVD, may provide better opportunities to reduce their cardiovascular risk.
Source: Diabetes Care - November 11, 2021 Category: Endocrinology Source Type: research

Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
CONCLUSIONSIn patients with T2DM and ASCVD, cluster analysis identified four clinically distinct groups. Further cardiovascular phenotyping is warranted to inform patient care and optimize clinical trial designs.
Source: Diabetes Care - October 29, 2021 Category: Endocrinology Source Type: research

Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
CONCLUSIONS The nonspecific, long-acting sulfonylureas glyburide and glimepiride do not have an increased risk of cardiovascular adverse events compared with the specific, short-acting sulfonylureas gliclazide, glipizide, and tolbutamide. However, nonspecific, long-acting sulfonylureas glyburide and glimepiride have an increased risk of severe hypoglycemia.
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Douros, A.; Yin, H.; Yu, O. H. Y.; Filion, K. B.; Azoulay, L.; Suissa, S. Tags: Epidemiology-Cardiovascular Disease Epidemiology/Health Services Research Source Type: research

Longitudinal Change in Fasting Blood Glucose and Myocardial Infarction Risk in a Population Without Diabetes
CONCLUSIONS We found that discrete FBG trajectories were significantly associated with subsequent risk of MI in individuals without diabetes. These observations suggest that long-term trajectories of FBG may be important for risk prediction of MI and possibly other macrovascular diseases.
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Jin, C.; Chen, S.; Vaidya, A.; Wu, Y.; Wu, Z.; Hu, F. B.; Kris-Etherton, P.; Wu, S.; Gao, X. Tags: Epidemiology-Cardiovascular Disease Cardiovascular and Metabolic Risk Source Type: research

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
Reductions in cardiovascular (CV) outcomes in recently reported trials, along with the recent approval by the U.S. Food and Drug Administration of an additional indication for empagliflozin to reduce the risk of CV death in type 2 diabetes patients with evidence of CV disease, have renewed interest in CV outcome trials (CVOTs) of glucose-lowering drugs. Composite end points are a pragmatic necessity in CVOTs to ensure that sample size and duration of follow-up remain reasonable. Combining clinical outcomes into a composite end point increases the numbers of events ascertained and thus statistical power and precision. Histo...
Source: Diabetes Care - August 22, 2017 Category: Endocrinology Authors: Marx, N.; McGuire, D. K.; Perkovic, V.; Woerle, H.-J.; Broedl, U. C.; von Eynatten, M.; George, J. T.; Rosenstock, J. Tags: Perspectives in Care Source Type: research

The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV: A Survey From the European Society of Cardiology
CONCLUSIONS The 2h-PG, in contrast to FPG and HbA1c, provides significant prognostic information regarding cardiovascular events in patients with CAD. Furthermore, elevated 2h-PG and HbA1c are significant prognostic indicators of an increased risk of incident diabetes.
Source: Diabetes Care - August 22, 2017 Category: Endocrinology Authors: Shahim, B.; De Bacquer, D.; De Backer, G.; Gyberg, V.; Kotseva, K.; Mellbin, L.; Schnell, O.; Tuomilehto, J.; Wood, D.; Ryden, L. Tags: Epidemiology-Clinical-Diagnosis and Screening Cardiovascular and Metabolic Risk Source Type: research

Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Hyperglycemia is the major risk factor for microvascular complications in patients with type 2 diabetes (T2D). However, cardiovascular disease (CVD) is the principal cause of death, and lowering HbA1c has only a modest effect on reducing CVD risk and mortality. The recently published LEADER and SUSTAIN-6 trials demonstrate that, in T2D patients with high CVD risk, the glucagon-like peptide 1 receptor agonists liraglutide and semaglutide reduce the primary major adverse cardiac events (MACE) end point (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% and 24%, respectively. The EMPA-REG OUTCOME, ...
Source: Diabetes Care - June 21, 2017 Category: Endocrinology Authors: Abdul-Ghani, M.; DeFronzo, R. A.; Del Prato, S.; Chilton, R.; Singh, R.; Ryder, R. E. J. Tags: Epidemiology-Diabetes Complications Perspectives in Care Source Type: research

Declining Trends of Cardiovascular-Renal Complications and Mortality in Type 2 Diabetes: The Hong Kong Diabetes Database
CONCLUSIONS From this territory-wide Hong Kong Diabetes Database, we observed decreases in incidence of cardiovascular-renal complications and death and corresponding improvements in risk factor control over a 13-year period.
Source: Diabetes Care - June 21, 2017 Category: Endocrinology Authors: Luk, A. O. Y.; Hui, E. M. T.; Sin, M.-C.; Yeung, C.-Y.; Chow, W.-S.; Ho, A. Y. Y.; Hung, H.-F.; Kan, E.; Ng, C.-M.; So, W.-Y.; Yeung, C.-K.; Chan, K.-S.; Chan, K.-W.; Chan, P.-F.; Siu, S.-C.; Tiu, S.-C.; Yeung, V. T. F.; Chan, J. C. N.; Chan, F. W. K.; Ch Tags: Epidemiology/Health Services Research Source Type: research

Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study
CONCLUSIONS The presence of major ECG abnormalities is associated with an increased risk of CVD in patients with type 1 diabetes. This suggests a potential role for ECG screening in patients with type 1 diabetes to identify individuals at risk for CVD.
Source: Diabetes Care - May 22, 2017 Category: Endocrinology Authors: Soliman, E. Z.; Backlund, J.-Y. C.; Bebu, I.; Orchard, T. J.; Zinman, B.; Lachin, J. M.; the DCCT/EDIC Research Group Tags: Cardiovascular and Metabolic Risk Source Type: research

Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators
CONCLUSIONS A large initial HbA1c reduction and achievement of low HbA1c levels within 6 months after metformin initiation are associated with a lower risk of cardiovascular events and death in patients with type 2 diabetes.
Source: Diabetes Care - May 22, 2017 Category: Endocrinology Authors: Svensson, E.; Baggesen, L. M.; Johnsen, S. P.; Pedersen, L.; Norrelund, H.; Buhl, E. S.; Haase, C. L.; Thomsen, R. W. Tags: Cardiovascular and Metabolic Risk Source Type: research

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
CONCLUSIONS Among older patients with well-controlled type 2 diabetes and cardiovascular disease, sitagliptin had neutral effects on cardiovascular risk and raised no significant safety concerns.
Source: Diabetes Care - March 20, 2017 Category: Endocrinology Authors: Bethel, M. A.; Engel, S. S.; Green, J. B.; Huang, Z.; Josse, R. G.; Kaufman, K. D.; Standl, E.; Suryawanshi, S.; Van de Werf, F.; McGuire, D. K.; Peterson, E. D.; Holman, R. R.; for the TECOS Study Group Tags: Emerging Science and Concepts for Management of Diabetes and Aging Source Type: research

Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes
CONCLUSIONS The absolute risk of thromboembolism among women with type 1 or 2 diabetes using hormonal contraception is low. Highly effective, intrauterine and subdermal contraceptives are excellent options for women with diabetes who hope to avoid the teratogenic effects of hyperglycemia by carefully planning their pregnancies.
Source: Diabetes Care - January 19, 2017 Category: Endocrinology Authors: OBrien, S. H.; Koch, T.; Vesely, S. K.; Schwarz, E. B. Tags: Epidemiology/Health Services Research Source Type: research

Pages: 1  2  3  4